Prof José Manuel Barroso, Chair of the Gavi Board, and Gavi CEO (ad int) David Marlow on achievements and challenges in 2022, and priorities and goals for 2023.
On 18 August 2023, the World Health Organisation (WHO) classified BA.2.86 as a ‘variant under monitoring (VUM)’ after the report of hyper-mutated BA.2.86 subvariant from multiple countries.